Transforming cancer treatment and advancing new therapies through empowered science.
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to...
NASDAQ | SGEN (Common Stock)
08/26/16 4:00 p.m. ET
Minimum 20 minute delay
Latest Investor Information
Press ReleasesTakeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma 08/01/16Seattle Genetics Reports Second Quarter 2016 Financial Results 07/26/16
Events2nd Quarter 2016 Financial Results07/26/16 4:30 p.m. ETView eventUBS Global Healthcare Conference05/24/16 10:30 a.m. ETView event
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|